Sales & Marketing

The rise in popularity of GLP-1 weight-loss drugs, such as Ozempic, Wegovy, and Mounjaro, has had a wide-reaching impact across the healthcare industry and beyond.

The approval of pembrolizumab (Keytruda; Merck) combined with gemcitabine and cisplatin for the treatment locally advanced unresectable or metastatic biliary tract cancer is the sixth sixth indication for the anti-PD-1 therapy for gastrointestinal cancers.

New subsidiary specializes in development of oral liquid products.

In the ever-evolving landscape of healthcare, it's vital for organizations to take steps toward bridging the gap between their clinical and marketing teams.

Collaboration aims to expand space research in studies of heart disease and diabetes.

Joint venture aims to seamlessly deliver Dyanavel through Perigon’s digital pharmacy.

Merger expected to expand company’s existing complementary platform of organ manufacturing programs.

Treatment marks company’s first approval for a type of inflammatory bowel disease.

Parties will establish a Center of Excellence in CMIC’s NJ plant.

Company aims to develop functional antibodies for the treatment of immunological & inflammatory disorders.

Agreement aims to speed up the launch of endometriosis and androgenic alopecia treatment.

Collaboration to focus on advancing mRNA-based oncology therapeutics.

Company to discuss acquisition and expansion of executive leadership.

Collaboration to focus on biologics of Kurma’s portfolio companies.

Investigational therapy indicated for the treatment of systemic sclerosis.

New company to be publicly listed as Citius Oncology, Inc.

Deal includes rights to novel antibody for the treatment of inflammatory bowel disease.

Penbraya indicated as the first and only vaccine for the prevention of the five most common serogroups in adolescents.

Companies to jointly develop candidates with potential commercialization agreements included.

Joint venture combines GE’s background in ultrasound technology with Novo Nordisk’s experience with metabolic diseases.

LP-310 designated as an oral formulation of company’s LP-10 asset.

Transaction valued at approximately $3.1 billion.

Agreement includes option for PTC Therapeutics to sell up to all its retained royalties.

Extra capital brings overall funding to $59.5 million.

Initiative started as a response to climate change, company says.

Qlosi indicated for adult patients.

Etrasimod indicated for adult patients with moderate-to-severe diagnosis.

Drug supplier receives $3.45 billion in commitment in new financing.

Treatment indicated for patients with BRAF V600E-mutant metastatic form of disease.

Treatment previously received emergency use authorization by the FDA.